Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : BJCT-BIOJECT-needle less injection product -- Ignore unavailable to you. Want to Upgrade?

To: The Ox who wrote (507)	3/21/2014 5:44:36 PM
From: Dwayne Hines	Respond to of 534

Yes, the company needed to do that, got it done and now they push hard into the overseas markets.

To: The Ox who wrote (507)	4/22/2014 9:53:45 AM
From: Dwayne Hines	1 Recommendation Recommended By The Ox Respond to of 534

Great news - Wall Street Journal Article: online.wsj.com North American Distribution

To: The Ox who wrote (507)	5/12/2014 2:12:58 PM
From: Dwayne Hines	1 Recommendation Recommended By The Ox Respond to of 534

China!!!! finance.yahoo.com

To: The Ox who wrote (507)	6/7/2014 8:58:31 PM
From: Dwayne Hines	Respond to of 534

Bioject to Participate in World Vaccine Congress – Asia in Singapore June 9-12th Tigard, OR –May27, 2014 – Bioject Medical Technologies Inc. (OTC Pink: BJCT), a leading developer of needle-free injection systems announces participation in the World Vaccine Congress - Asia in Singapore June 9 – 12th. Bioject will be presenting its technology to vaccine company delegates, public health officials, and developers from throughout the region. Attending the conference will be Mark Logomasini, President and CEO and Dr. Richard Stout, Executive Vice President and Chief Medical Officer. In conjunction with the activities at the conference, Bioject will be hosting its first international distributor meeting. “We are looking forward to the opportunities this forum provides for Bioject to present and discuss our technology with senior vaccine attendees across Asia who will be present at this event,” said Mark Logomasini, Bioject’s President and CEO. “In addition to our presence, our distributors covering all of the countries, companies, and organizations will also be in attendance at the conference. Their involvement will help to formulate and execute on strategies to increase awareness and sales in these key markets.” Bioject Medical Technologies Inc., based in Tigard, Oregon, USA, is a developer and manufacturer of needle- free injection therapy systems (NFITS). NFITS works by forcing medication at high speed through a tiny orifice held against the skin. This creates a fine stream of high-pressure fluid penetrating the skin and depositing medication in the tissue beneath. Bioject is focused on developing mutually beneficial agreements with leading pharmaceutical, biotechnology, and veterinary companies, as well as research, global health and government organizations.